60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

뉴스 본문을 불러오고 있어요.

60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6 | 웨이프 WAPE

60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

기사 요약

관련 종목

댓글 —